Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.

Slides:



Advertisements
Similar presentations
To Bridge or Not to Bridge: Guide to Clinicians Hazem Elewa, RPh, PhD, BCPS Assistant Professor, College of Pharmacy, Qatar University.
Advertisements

2012 CHEST Guideline Update VTE prophylaxis, DVT treatment, and Atrial Fibrillation LT Tabatha Welker, PharmD Pharmacy Resident, PHS Claremore Indian Hospital.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
Question: How should we manage periprocedural anticoagulation? Paper: Management of Antithrombotic Therapy in Patients Undergoing Invasive Procedures Todd.
VTE in abdominal-pelvic surgery patients
CLINICAL CASES.
Antithrombotic Therapy for Venous Thromboembolic Diseases
Post oral surgery bleeding for adult patients receiving antithrombotic therapy.
Venous Thromboembolism Prevention August Venous Thromboembloism Prevention 2 Expected Practice  Assess all patients upon admission to the ICU for.
Venous Thromboembolism in the Surgical Patient: Prophylaxis and Treatment Pamela Hebbard August 11, 2005.
Prophylaxis of Venous Thromboembolism
Venous thromboembolism –
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Beverley Hunt Simon Noble Hospital Acquired Venous Thromboembolism.
Stroke prevention in atrial fibrillation
Anticoagulation? Antiplatelet? What’s the Score? COPYRIGHT © 2015, ALL RIGHTS RESERVED From the Publishers of.
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Venous thromboembolism: how long to treat?
Preventing Venous Thromboembolism in Surgical and Medical Patients Susan Kahn MD MSc Director, JGH Thrombosis Program March 2011.
LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Medical Patients – VTE Prevention Dale W. Bratzler, DO, MPH Professor and Associate Dean, College of Public Health Professor of Medicine, College of Medicine.
DVT Prophylaxis in Orthopedic Patients Rogers Kyle 11/27/12.
Indications for Perioperative Bridging Ann McBride, M.D. UW Anticoagulation Service.
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
Thromboprophylaxis in Pregnancy and the Puerperium
Prevention Of Venous Thromboembolism In The Cancer Surgical Patient A K Kakkar Barts and the London School of Medicine and Thrombosis Research Institute,
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.
Venous Thromboembolism
Prevention of Venous Thromboembolism 8 th ACCP Guidelines Chest 2008.
VTE Prevention In Action Interactive Case Scenarios.
A New Oral Direct Thrombin Inhibitor, Dabigatran Etexilate, Compared With Enoxaparin for Prevention of Thromboembolic Events Following Total Hip or Knee.
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
How Do You Manage Anticoagulants and Antiplatlet Agents? Steve Schrock, MD, FAAFP November 5, 2015.
Anticoagulation ACCP guidelines 2012
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Drugs Susan Louw Haematology Registrar. 4 Questions to ask: Can I stop? (What is the risk of thrombosis?) Should I stop? (What is the risk of bleeding?)
Dabigatran Etexilate is Effective and Safe for the Extended Prevention of Venous Thromboembolism Following Total Hip Replacement Eriksson BI, Dahl OE,
ANTI-COAGULATION. ENOXAPARIN DOSING Obesity (BMI >= 40 kg/m2) – may increase prophylactic dose by 30% such as in bariatric surgery Abdominal Surgery ….
Perioperative Management of Antithrombotic Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Nathan P. Clark, Pharm D, FCCP, BCPS Clinical Pharmacy Supervisor Clinical Pharmacy Anticoagulation and Anemia Service Kaiser Permanente Colorado Aurora,
G UIDELINES FOR THE P ERI -P ROCEDURAL M ANAGEMENT OF A DULTS T AKING T ARGET S PECIFIC A NTICOAGULANTS (TSOAC S ): DABIGATRAN, RIVAROXABAN, APIXABAN,
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Mike Kolber BSc, MD, CCFP, MSc AAPCE Nov. 3, 2012.
Dr. Hadab A. Mohamed. BACKGROUND Temporary interruption Thrombotic risk Continuation Bleeding risk A great challenge, especially in the emergency setting.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
Low Procedural Bleed Risk
The management of anti-thrombotics in patients undergoing GI endoscopy
Canadian Cardiovascular Society Antiplatelet Guidelines
Management of Patients on Chronic Oral Anticoagulant Therapy
Perioperative Management of Antithrombotic Therapy
You can never be too Thin…. An Update on NOACs
Antithrombotic Therapy in Atrial Fibrillation
Ortho Warfarin Dosing Protocol
Prevention of Venous Thromboembolism in Orthopedic Surgery Patients
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Periprocedural Management of Patients on Anticoagulation
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
Prevention and Management of Venous Thromboembolic Events in Patients With Multiple Myeloma.
Presentation transcript:

Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research Institute

Today Peri-operative bridging –Warfarin –ASA –Clopidogrel Post-operative Thromboprophylaxis –Orthopedic surgery –General surgery

Peri-op bridging (warfarin)

Dilemma: Pre and Post-op Risk assessment Preventable thromboembolism Major bleeds

Pharmacokinetics INR will normalise in a time period ranging from 50 to over 200 hours but 23% remain higher than 1.2 five days after d/c OACs

INR after warfarin induction When reinitiated a therapeutic level of anticoagulation will be achieved in a variable time period ranging from 2 to 10 days When OACs are discontinued and re-initiated the length of time with sub-therapeutic INRs is highly variable As a consequence clinicians need to consider “bridging therapy”

Assessment of Thrombosis Risk Venous Vs Arterial Thrombosis

Arterial Thrombosis – High risk CHADS2 Congestive Heart Failure 1 Hypertension1 Age >701 Diabetes1 Stroke/TIA2 Total 0-2: %/yr stroke > 2: %/yr stroke

Risk of Bleeding from Procedure Low Risk Procedure –Dental procedure –Skin Biopsy –Cataract surgery –GI: Diagnostic colonoscopy or endoscopy EGD +/- biopsy Flexible Sphincteromy+/- biopsy Biliary/pancreatic stent ERCP without sphincterotomy Moderate or High risk

Bleeding risk→ Thrombosis Risk↓ LowHigh Low High Bridge STOP

Bridging with LMWH D -5 OR D5-10 Clinic Home Local lab X

Summary (pre-op) Stop warfarin 5 days before surgery Assess need for peri-operative bridging High risk: Therapeutic LMWH > IV UFH Moderate risk: Therapeutic > prophylactic LMWH > IV UFH Low risk: no bridging or prophylactic LMWH If therapeutic LMWH is used: –50% therapeutic dose on OR day -1 –No need to follow anti-Xa levels If prophylactic LMWH is used: –Last dose 24 hours before OR If IV UFH is used: Stop infusion 4 hours pre-op STAT INR 1-2 days before OR day If INR > 1.5 give 1-2 mg of PO vitamin K

Summary (post-op) Resume VKA 12 to 24 hours post op Good hemostasis PO intake Epidural is out Resuming Post-op LMWH bridging is POD1 if good hemostasis If using therapeutic doses of LMWH/UFH »POD1 if minor surgical procedure »Consider resuming on POD2 if high bleeding risk major surgery »No need to follow anti-Xa D/C LMWH or UFH once INR therapeutic –i.e. > 2.0 or 2.5 depending on indication

Peri-op bridging (ASA, clopidogrel)

ASA/Clopidogrel If not high risk for cardiac events: –Stop 7 to 10 days before the procedure –Resume on POD1 (24 hours post-op) Adequate hemostasis If high risk of cardiac events (exclusive of coronary stents) for non- cardiac surgery Continue aspirin Hold clopidogrel at least 5 days and preferable within 10 days of surgery If high risk of cardiac events (exclusive of coronary stents) for CABG Same as above If ASA is interrupted then needs to be reinitiated between 6 and 48 hours after CABG

ASA/Clopidogrel Coronary stent If bare metal coronary stent within 6 weeks –Continue ASA and clopidogrel peri-operatively If drug-eluting stent within 12 months –Continue ASA and clopidogrel peri-operatively In patients with coronary stents who have interruption of ASA or clopidogrel –No need to routinely bridge these patients

Prevention of Venous Thromboembolism

General Principles Should think about thromboprophylaxis for every patients Mechanical methods alone in patients at high risk of bleeding only! May be used as an adjunct to anticoagulant The use of ASA alone as thromboprophylaxis is not recommended for any patient group!

What is the risk?

Risk factors for VTE

General Surgery Low-risk general surgery patients undergoing minor procedure No need for thromboprophylaxis Early and frequent ambulation Moderate-risk general surgery patients who are undergoing a major procedure for benign disease LMWH, IFH sc TID or BID, or fondaparinux Higher-risk general surgery patients who are undergoing a major procedure for cancer LMWH, UFH sc TID or fondaparinux Continue thromboprophylaxis until discharge except: Cancer patients: at least 7 to 10 days Cancer patients + other risk factors: up to 28 days

General Surgery Entirely laparoscopic surgery procedure with no additional thromboembolic risk factors No need for thromboprophylaxis Early and frequent ambulation If additional VTE risk factors then thromboprophylaxis until D/C home (unless cancer)

Orthopedic Surgery LMWH –Prophylactic doses –Dalterapin 5000 IU OD, enoxaparin 40 mg OD or 30 mg bid, tinzaparin 4500 IU OD –Starting on POD1 Fondaparinux (2.5 mg started 6 to 24 hours post-op) Warfarin –target INR Rivaroxaban –10 mg OD Dabigatran –220 or 150 mg OD Not ASA, mechanical methods alone, dextran, or UFH

Duration THR, TKR or HFS: At least 10 days THR, HFS: Thromboprophylaxis should be extended beyond 10 days and up to 35 days TKR: Can consider extending thromboprophylaxis beyond 10 days and up to 35 days Knee arthroscopy: No need for thromboprophylaxis if no other VTE risk factors If other risk factors, consider LMWH

Trauma Thromboprophylaxis if possible LMWH alone LMWH + mechanical methods Hold LMWH if high risk of bleeding –Don’t forget to resume… No screening U/S for DVT No IVC filter insertion as thromboprophylaxis Continue thromboprophylaxis until hospital D/C If patient undergoes inpatients rehab: Switch to warfarin (target ) until D/C home Or continue LMWH prophylaxis

Thank You